BIOGEN INC (BIIB) Stock Fundamental Analysis

NASDAQ:BIIB • US09062X1037

194.13 USD
-1.49 (-0.76%)
At close: Feb 18, 2026
193.14 USD
-0.99 (-0.51%)
Pre-Market: 2/19/2026, 8:07:17 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Overall BIIB gets a fundamental rating of 5 out of 10. We evaluated BIIB against 521 industry peers in the Biotechnology industry. Both the profitability and the financial health of BIIB get a neutral evaluation. Nothing too spectacular is happening here. BIIB has a bad growth rate and is valued cheaply. With these ratings, BIIB could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year BIIB was profitable.
  • In the past year BIIB had a positive cash flow from operations.
  • Of the past 5 years BIIB 4 years were profitable.
  • BIIB had a positive operating cash flow in 4 of the past 5 years.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

  • BIIB has a Return On Assets of 5.51%. This is amongst the best in the industry. BIIB outperforms 91.75% of its industry peers.
  • The Return On Equity of BIIB (8.84%) is better than 92.13% of its industry peers.
  • The Return On Invested Capital of BIIB (9.70%) is better than 94.43% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 18.69%.
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROIC 9.7%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • The Profit Margin of BIIB (15.98%) is better than 92.13% of its industry peers.
  • BIIB's Profit Margin has declined in the last couple of years.
  • BIIB has a better Operating Margin (28.50%) than 96.74% of its industry peers.
  • BIIB's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 75.24%, BIIB belongs to the top of the industry, outperforming 84.07% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BIIB has declined.
Industry RankSector Rank
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
  • BIIB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • BIIB has an Altman-Z score of 3.44. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
  • BIIB has a Altman-Z score of 3.44. This is in the better half of the industry: BIIB outperforms 68.71% of its industry peers.
  • BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as BIIB would need 2.78 years to pay back of all of its debts.
  • BIIB has a Debt to FCF ratio of 2.78. This is amongst the best in the industry. BIIB outperforms 92.51% of its industry peers.
  • A Debt/Equity ratio of 0.35 indicates that BIIB is not too dependend on debt financing.
  • The Debt to Equity ratio of BIIB (0.35) is worse than 68.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Altman-Z 3.44
ROIC/WACC1.17
WACC8.26%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.72 indicates that BIIB has no problem at all paying its short term obligations.
  • The Current ratio of BIIB (2.72) is worse than 68.52% of its industry peers.
  • BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.04, BIIB is not doing good in the industry: 73.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.04
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • BIIB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
  • The earnings per share for BIIB have been decreasing by -14.17% on average. This is quite bad
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%

3.2 Future

  • Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 3.54% on average per year.
  • BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.42% yearly.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-0.42%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.70, BIIB is valued correctly.
  • BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.31% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.27, BIIB is valued rather cheaply.
  • The Price/Forward Earnings ratio is 12.76, which indicates a correct valuation of BIIB.
  • 97.31% of the companies in the same industry are more expensive than BIIB, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of BIIB to the average of the S&P500 Index (28.16), we can say BIIB is valued rather cheaply.
Industry RankSector Rank
PE 12.7
Fwd PE 12.76
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.89% of the companies listed in the same industry.
  • 97.70% of the companies in the same industry are more expensive than BIIB, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.59
EV/EBITDA 8.46
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BIIB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOGEN INC

NASDAQ:BIIB (2/18/2026, 8:16:06 PM)

Premarket: 193.14 -0.99 (-0.51%)

194.13

-1.49 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner Change0.81%
Ins Owners0.15%
Ins Owner Change7.98%
Market Cap28.49B
Revenue(TTM)N/A
Net Income(TTM)1.61B
Analysts73.33
Price Target195.32 (0.61%)
Short Float %3.2%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)6.51%
PT rev (3m)11.59%
EPS NQ rev (1m)2.98%
EPS NQ rev (3m)2.55%
EPS NY rev (1m)0.25%
EPS NY rev (3m)-1.61%
Revenue NQ rev (1m)0.18%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE 12.7
Fwd PE 12.76
P/S 2.83
P/FCF 12.59
P/OCF 11.61
P/B 1.56
P/tB 11.95
EV/EBITDA 8.46
EPS(TTM)15.29
EY7.88%
EPS(NY)15.21
Fwd EY7.84%
FCF(TTM)15.42
FCFY7.94%
OCF(TTM)16.72
OCFY8.61%
SpS68.59
BVpS124.06
TBVpS16.25
PEG (NY)N/A
PEG (5Y)N/A
Graham Number206.59
Profitability
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROCE 11.07%
ROIC 9.7%
ROICexc 11.44%
ROICexgc 40.96%
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
FCFM 22.48%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Debt/EBITDA 1.73
Cap/Depr 25.04%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 67.56%
Profit Quality 140.63%
Current Ratio 2.72
Quick Ratio 2.04
Altman-Z 3.44
F-Score5
WACC8.26%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-0.42%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.43%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%

BIOGEN INC / BIIB FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


How profitable is BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a profitability rating of 6 / 10.


How financially healthy is BIOGEN INC?

The financial health rating of BIOGEN INC (BIIB) is 6 / 10.